PCQI Insights
PCQI Scope and Drug Classification: Where Preventive Controls End
Quick answer: a PCQI prepares or oversees certain food safety plan work under 21 CFR Part 117. That role does not cover drug classification. Disease claims on labels, websites or inserts can make a product a drug, so a PCQI should route them to regulatory review.
PCQI scope and drug classification are two separate questions. When a product is promoted to treat, prevent, mitigate or cure a disease, that language can change how FDA classifies the product. Such statements may appear on packaging, ecommerce pages, blogs, leaflets and materials shipped with orders.
So assess the product’s intended use and its records before therapeutic language reaches the U.S. market. For a PCQI, the priority is to apply the right compliance framework. Food safety training, certification or import documents do not authorize drug claims. For the claims themselves, see our guide to dietary supplement disease claims.
Where PCQI Scope Ends Under Part 117
What the PCQI role covers
Under 21 CFR 117.180(a), one or more PCQIs must do or oversee specific tasks. These include preparing the food safety plan, validating preventive controls, reviewing records and reanalyzing the plan.
A PCQI qualifies through training in risk-based preventive controls or through job experience, as defined in 21 CFR 117.3. None of these duties includes approving health or disease claims.
When Part 117 preventive controls do not apply
Many supplement makers are outside these duties entirely. Under 21 CFR 117.5(e), subparts C and G do not apply to manufacturing, processing, packaging or holding a dietary supplement in compliance with Part 111 and section 761 of the FD&C Act.
In that case, subpart C PCQI duties may not apply at all. Instead, Part 111 dietary supplement CGMP principally governs manufacturing. Our article on which FDA rules apply to supplements explains this split in more detail.
How Drug Classification Depends on Intended Use
The statutory drug definition
Under 21 U.S.C. 321(g)(1), the term drug includes articles intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease. In other words, the intended use can matter as much as the formula.
According to 21 CFR 201.128, intended use refers to the objective intent of the persons legally responsible for the labeling. Labeling claims, advertising matter and oral or written statements can all show that intent.
Disease claims for dietary supplements
21 CFR 101.93(g) defines disease claims for dietary supplements. Under 101.93, a product marketed as a dietary supplement whose labeling bears such a claim is subject to regulation as a drug, unless it is an authorized health claim for which the product qualifies.
Hazard analysis is not an intended-use review
A hazard analysis under 21 CFR 117.130 evaluates food safety hazards in the process. However, disease-treatment claims may establish drug intended use even when processing is well controlled. A clean food safety plan therefore says nothing about whether a claim is lawful.
How a PCQI Hands Off Claims Questions
1. Identify the applicable product and facility rule
First, assess whether Part 117 preventive controls apply, whether Part 111 dietary supplement CGMP applies, or whether another regulatory pathway governs the product.
2. Treat claims as a separate escalation point
Next, have regulatory or legal specialists evaluate any proposal that mentions treating, preventing or mitigating a specific disease. The PCQI flags the issue but does not approve the wording. The same split applies to broader supplement marketing claims.
3. Keep product facts aligned
Make sure specifications, labeling facts and product descriptions match approved technical records and regulatory decisions.
4. Build claims review into document control
Use written review criteria, approvals and staff training. In addition, set a working procedure to withdraw inaccurate promotional copy. A records platform such as SystemsBuilder can hold approved wording and change history, although software does not replace a product-specific regulatory assessment.
5. Verify that corrections took effect
If claims change, confirm the corrections on live pages, blogs, inserts, labels, partner listings and archived campaign assets where applicable. After all, the right time to improve claims governance is before an unresolved content gap becomes a regulatory concern.
PCQI Scope and Drug Classification Checklist
✓ Confirm the product category, intended use and responsible reviewer.
✓ Inventory packaging, website content, blogs, product inserts and relevant third-party listings.
✓ Flag disease-treatment and disease-prevention statements for regulatory assessment.
✓ Keep current approved wording, reviewer decisions and change history.
✓ Document corrective actions and verify that affected materials were updated.
Frequently Asked Questions
Does a PCQI credential authorize health or disease claims?
No. PCQI training relates to preventive controls responsibilities under Part 117. It is not FDA approval of drug-related claims.
Do dietary supplement manufacturers automatically follow Part 117 preventive controls?
No. Applicability and exemptions must be assessed. Under 21 CFR 117.5(e), supplement operations in compliance with Part 111 are exempt from subparts C and G, and Part 111 CGMP principally governs them.
What should a PCQI do if a promotional claim is concerning?
Escalate it to the appropriate regulatory decision-maker. Then document any changes to related product information where relevant.
Official References
21 CFR Part 117
21 CFR Part 111
21 CFR 101.93
21 CFR 201.128
21 U.S.C. 321
PCQI Insights
Related Reading
PCQI Requirements vs FDA Dietary Supplement Disease Claims
Why disease claims are not a PCQI sign-off issue, and how Part 111 and Part 117 divide the work.
Read article →
PCQI vs. Dietary Supplement Website Claims
How blogs and sales pages can create drug intended use, and what a food safety plan does not cover.
Read article →
Dietary Supplement CGMP: Which FDA Rules Apply?
How the PCQI role relates to dietary supplement CGMP obligations under Part 111.
Read article →
Need Help Managing Your PCQI Responsibilities?
Talk with our team about Part 117 applicability, your food safety plan and how claims questions are routed for review.
Independent educational content. PCQI Services is not affiliated with or endorsed by the U.S. Food and Drug Administration (FDA). This article is for general educational and informational purposes only and does not constitute regulatory approval, certification or legal advice. Regulatory applicability must be assessed for each product, facility and operation. Read our terms.
